Alcresta Therapeutics Announces RELiZORB® (iMMOBILIZED LIPASE) CARTRIDGE has been Issued a Unique Q-Code (Q9994) by CMS

WARREN, N.J. – June 18, 2018 – Alcresta Therapeutics, Inc. today announced the issuance of a unique Q-code by CMS for its digestive enzyme cartridge RELiZORB. RELiZORB (iMMOBILIZED LIPASE) CARTRIDGE is an in-line digestive enzyme cartridge and is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula.  The code, Q9994, is effective July 1, 2018.  CMS has instructed Medicare Administrative Contractors to add Q9994 to the relevant code set as of that date.

As CMS explained, “such coding is necessary for Medicare, Medicaid, and other health insurance programs to ensure that insurance claims are processed in an orderly and consistent manner.”

“We are pleased that CMS has recognized the need for a unique billing code for RELiZORB,” said Daniel Tassé, CEO of Alcresta Therapeutics.

About Alcresta® Therapeutics, Inc.

Alcresta Therapeutics, Inc. is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency, which results in malabsorption common in cystic fibrosis, digestive cancers, premature birth, and other serious diseases.

The Alcresta Therapeutics, Inc. management team has extensive experience in pharmaceutical, medical devices, and nutritional product development. The corporate office is based in Warren, New Jersey with additional R&D sites in the Boston, MA area and is backed by top-tier investors: Athyrium Capital Management, Bessemer Venture Partners, HealthQuest Capital, Frazier Healthcare Partners, and Third Rock Ventures. More information can be found at


Internal Media Contact:

Daniel Tassé

Chief Executive Officer

Alcresta Therapeutics, Inc.